eligibility_summary
Adults ≥18 with newly diagnosed Ph+/BCR-ABL1+ ALL, no prior TKIs/chemo (preconditioning ok), ECOG ≤2, survival ≥3 mo, adequate organ function: liver/renal, amylase/lipase, EF>50%, PASP ≤50 mmHg, QTc ≤450/470 ms, coag ≤1.5×ULN, able to comply. Exclude HIV/HBV/HCV, uncontrolled infection, active autoimmune/CNS, cardiac/vascular disease or QT‑prolonging meds, bleeding, other malignancy, pancreatitis/alcohol abuse, TG ≥5.6, pregnancy/breastfeeding, major surgery <14 d, noncompliance, other risks.
trial_source
clinical_trials.gov from Dec 2, 2025
annotation_status
ai
ai_summary
Trial tests olverembatinib plus blinatumomab in adult de novo Ph+ ALL. Olverembatinib: third‑generation small‑molecule tyrosine kinase inhibitor targeting BCR‑ABL1 (including T315I), blocking oncogenic kinase signaling and leukemic cell proliferation/survival. Blinatumomab: bispecific T‑cell engager (BiTE) antibody construct that binds CD19 on B‑cell blasts and CD3 on T cells, redirecting T‑cell cytotoxicity to eliminate CD19+ leukemia and minimal residual disease. Targets: Ph+ CD19+ B‑lymphoblasts, BCR‑ABL1 pathway, engages CD3+ T cells for immune killing. Drug types: targeted therapy (TKI) + immunotherapy (BiTE).